Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.47 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | UBASH3B | Q8TF42 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758311 | 0.84 | LMNA (0.47) | SRD5A2KMT2AMEN1LMNARXFP1 | |
| SCHEMBL17025452 | 0.83 | KDM4E (0.49) | KDM4EALDH1A1SRD5A2KMT2AMEN1 | |
| SCHEMBL6992541 | 0.82 | KMT2A (0.43) | KDM4EPOLBTDP1L3MBTL1ALDH1A1 | |
| Water SCHEMBL5782423 | 0.78 | KMT2A (0.51) | KDM4EALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL5781874 | 0.77 | RHEB (0.48) | L3MBTL1SRD5A2KMT2AMEN1LMNA | |
| SCHEMBL1538310 | 0.76 | MEN1 (0.59) | KDM4EKMT2AMEN1LMNARXFP1 | |
| SCHEMBL5782115 | 0.76 | KMT2A (0.66) | KDM4EALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL1514486 | 0.75 | POLB (0.70) | KDM4EPOLBTDP1L3MBTL1ALDH1A1 | |
| SCHEMBL6990287 | 0.75 | KDM4E (0.46) | KDM4ETDP1ALDH1A1NR4A1SRD5A2 | |
| SCHEMBL5756005 | 0.75 | MEN1 (0.44) | KMT2AMEN1LMNARXFP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129356-B2 | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-31 | — | — | US | disclosed |
| US-20060135769-A1 | Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives | ANGIBAUD PATRICK R | 2006-06-22 | — | — | US | disclosed |
| EP-1351954-B1 | FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2006-05-03 | — | — | EP | disclosed |
| EP-1347966-B1 | FARNESYL TRANSFERASE INHIBITING 4-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2006-03-08 | — | — | EP | disclosed |
| US-20040067968-A1 | Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-08 | — | — | US | disclosed |
| US-20040063944-A1 | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-04-01 | — | — | US | disclosed |
| EP-1351954-A1 | FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1347966-A1 | FARNESYL TRANSFERASE INHIBITING 4-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002051835-A1 | FARNESYL TRANSFERASE INHIBITING 4-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-07-04 | — | — | WO | disclosed |
| WO-2002051834-A1 | FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067968-A1 | Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline | FNTA, FNTB, ACAT2 | KDM4E 2268/4885POLB 4404/4885TDP1 2139/4885 |
| US-20040063944-A1 | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives | FNTA, FNTB, CYP7A1 | KDM4E 2357/4885POLB 4346/4885TDP1 2754/4885 |
| US-20060135769-A1 | Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives | FNTA, FNTB, RABGGTB | KDM4E 2411/4885POLB 4616/4885TDP1 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.